Heads up: I made a mistake on this one when it first went up on the site. We strive for at least a 99% accuracy rate in identifying teaser targets, and this is apparently my mistake for 2014. Thanks to several readers for alerting me to the fact that I moved too quickly in posting this one and made an error.
It looks like the BioScience Millionaire trading service by Ernie Tremblay over at Money Map Press has now been renamed Biotech Insider Alert… but the focus seems to be the same, with a goal of investing based in large part on the timing of FDA decisions and other science-based milestones for biotech companies (they launched this newsletter earlier in the year with the boast that they had a handle on the “most profitable calendar known to man”).
Which isn’t unusual, of course — biotech stocks, particularly those which don’t have any products for sale (and won’t for years) trade based on the development of their product pipeline, with reports on efficacy and safety moving the needle and the big decisions, like FDA approvals or partnership agreements or other key steps in the development process, often having a large impact on stock prices.
And Tremblay’s publisher, Mike Ward, has a new ad out promoting the service — all built on the promise that a move by the FDA will “ignite” this tiny stock. He throws around numbers that make you salivate, like sales going from $28 million to $1.5 billion, and the share price going from $4 to $143.
So what’s the stock? Well, they’d be happy to tell you all about it… for $5,000 (OK it’s “on sale” for $1,950). What if you don’t really want your report and you’re just kind of curious about the stock and want to research it for yourself? Well, we can help with that — let’s dig into the clues and figure out who they’re talking about.
Here’s the lead-in:
“Hi, I’m Mike Ward, Publisher of Money Map Press.
“I just wrote this check for $40,000 for a very specific reason.
“I believe in a very short time this $40,000 will be worth many times that value.
“It’s because of a very special situation I recently learned about…
“One that involves some of the smartest research scientists in America… and a breakthrough they’re making that
“I believe could be worth more than $1.5 billion dollars to one small company.
“Right now, this company has annual sales of $28 million.
“So that’s an increase in revenue of more than 53 times. The market value of this company could reach dizzying new heights.”
The check was a donation that Ward made at the behest of Ernie Tremblay, here’s how Tremblay describes it later on in the ad:
“I believe so much in this tiny $4 company and its breakthrough drug…
“That I convinced my publisher to donate 10,000 shares of its stock to the Ocular Immunology & Uveitis Foundation.
“And I can’t think of a more worthy cause…
“The Uveitis Foundation is a non-profit organization working to provide education, care, and emotional support for victims of Uveitis.
“They rely on the generosity of others, and that’s exactly what we’re giving them.
“In fact, I don’t have one shred of doubt about this tiny company and the value of the gift we’re giving the Foundation.
“I’m 100% confident in their veteran management team… their drug… and the hard science behind it.Are you getting our free Daily Update
"reveal" emails? If not,
just click here...
“And I’m even more confident that their $4 stock is about to go on a run that could make shareholders – including the Uveitis Foundation – very rich.
“Based on my price target calculations, that $40,000 stock donation could soon be worth $1.4 million.
“And when I say soon, I mean any day now.